News | February 23, 2024
AstraZeneca completes acquisition of Gracell
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The launch of a DGCA Type Approved Logistics Drone facilitates critical medical deliveries to remote regions
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Subscribe To Our Newsletter & Stay Updated
